Drugs Licensing Radiology 
pharmaphorum
MARCH 31, 2021
Novartis has added to its pipeline of radiopharmaceuticals pipeline once again, licensing a series of agents from iTheranostics that can be used to show where tumours are located in the body. . Novartis licenses the drug from Genmab and reformulated into its Sensoready autoinjector pen. In 2018 it paid $2.1
XTalks
SEPTEMBER 9, 2022
This week, Magnus Medical’s SAINT Neuromodulation System received 510(k) clearance from the US Food and Drug Administration (FDA) for the treatment of major depressive disorder (MDD) in adults who did not have satisfactory improvement from past antidepressant medications in their current episode.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
OCTOBER 4, 2022
On 27th September 2022, the Food and Drug Administration (FDA) issued its final guidance for industry and FDA staff clinical decision support (CDS) software, which has been anticipated since the Center for Devices and Radiological Health (CDRH) listed the guidance as a top priority for fiscal year 2022. Criteria for regulation.
pharmaphorum
APRIL 7, 2021
In its second licensing deal in the radio-oncology area in consecutive weeks, Novartis has agreed a $1.3 Novartis has made radioligands one of four pillars of its cancer business, along with cell and gene therapy, targeted drugs and immunotherapeutics, and has been steadily bolting on assets to expand its pipeline in this area.
Advarra
APRIL 30, 2024
A cross-check ensures curriculum vitae (CVs), and medical licenses (if appropriate) are on file and current. For example, most hospital radiology technicians are trained to perform scans for the hospital and/or PI for clinical trials based on the information in the test requisitions. Form FDA 1572 The Form FDA 1572 is unique to U.S.
The Pharma Data
APRIL 15, 2022
Food and Drug Administration issued an emergency use authorization (EUA) for the first COVID-19 diagnostic test that detects chemical compounds in breath samples associated with a SARS-CoV-2 infection. director of the FDA’s Center for Devices and Radiological Health. Today, the U.S. for the next public health emergency.”.
The Pharma Data
JUNE 28, 2021
The companies acquired by Bayer, Noria and PSMA Therapeutics, have exclusive world-wide rights to technology licensed from Weill Cornell Medicine (New York, NY, USA) and Johns Hopkins University (Baltimore, MD, USA). Noria was founded by Dr. John Babich, Chief, Radiopharmaceutical Sciences in Radiology at Weill Cornell Medicine.
Expert insights. Personalized for you.
98 
Let's personalize your content